Welcome to the first issue of the Latham & Watkins Drug Pricing Digest. Here, Latham’s government price reporting team provides a digest of recent developments, as reported in the trade press or published directly by...more
5/10/2021
/ Antitrust Provisions ,
Drug Pricing ,
Healthcare Reform ,
Legislative Agendas ,
Life Sciences ,
MACPAC ,
Medicaid Reform ,
OIG ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B